Royalty Pharma plc operates in the biopharmaceutical industry.
Proven track record with mediocre balance sheet.
Share Price & News
How has Royalty Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RPRX has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how RPRX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RPRX performed against the US Market.
Price Volatility Vs. Market
How volatile is Royalty Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Royalty Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RPRX ($43.05) is trading below our estimate of fair value ($45.07)
Significantly Below Fair Value: RPRX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: Insufficient data to calculate RPRX's PE Ratio to determine if it is good value compared to the US Pharmaceuticals industry average.
PE vs Market: Insufficient data to calculate RPRX's PE Ratio to determine if it is good value compared to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RPRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: Insufficient data to calculate RPRX's PB Ratio to determine if it is good value.
How is Royalty Pharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RPRX's forecast earnings growth (2.8% per year) is above the savings rate (2.2%).
Earnings vs Market: RPRX's earnings (2.8% per year) are forecast to grow slower than the US market (22.2% per year).
High Growth Earnings: RPRX's earnings are forecast to grow, but not significantly.
Revenue vs Market: RPRX's revenue (7.7% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: RPRX's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RPRX's Return on Equity is forecast to be high in 3 years time (26.4%)
How has Royalty Pharma performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: RPRX has high quality earnings.
Growing Profit Margin: RPRX's current net profit margins are higher than last year (90%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RPRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare RPRX's past year earnings growth to its 5-year average.
Earnings vs Industry: RPRX earnings growth over the past year (26.7%) exceeded the Pharmaceuticals industry 12.1%.
Return on Equity
High ROE: RPRX's Return on Equity (30.4%) is considered high.
How is Royalty Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: RPRX's short term assets ($1.7B) exceed its short term liabilities ($434.0M).
Long Term Liabilities: RPRX's short term assets ($1.7B) do not cover its long term liabilities ($5.8B).
Debt to Equity History and Analysis
Debt Level: RPRX's debt to equity ratio (83.2%) is considered high.
Reducing Debt: Insufficient data to determine if RPRX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: RPRX's debt is well covered by operating cash flow (28.6%).
Interest Coverage: RPRX's interest payments on its debt are well covered by EBIT (10.7x coverage).
What is Royalty Pharma current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RPRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RPRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Pablo Legorreta (56 yo)
Mr. Pablo G. Legorreta serves as Chairman of the Board at Royalty Pharma plc and has been its Chief Executive Officer and Director since 1996. Mr. Legorreta co-founded RP Management LLC (also known as Roya ...
|Chairman of the Board & CEO||24.58yrs||no data||3.87% |
|Vice Chairman & Executive VP||0.58yr||no data||0.11% |
|Independent Director||0.17yr||no data||0.25% |
|Director||0.17yr||no data||1.11% |
|Independent Director||0.17yr||no data||0.089% |
|Independent Director||0.17yr||no data||0.026% |
|Independent Director||0.17yr||no data||no data|
|Director||0.17yr||no data||10.42% |
|Independent Director||0.17yr||no data||no data|
Experienced Board: RPRX's board of directors are not considered experienced ( 0.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RPRX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: RPRX only recently listed within the past 12 months.
Royalty Pharma plc's company bio, employee growth, exchange listings and data sources
- Name: Royalty Pharma plc
- Ticker: RPRX
- Exchange: NasdaqGS
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$26.133b
- Shares outstanding: 607.04m
- Website: https://www.royaltypharma.com
- Royalty Pharma plc
- 110 East 59th Street
- Floor 33
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RPRX||NasdaqGS (Nasdaq Global Select)||Yes||Class A Ordinary Shares||US||USD||Jun 2020|
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/03 00:18|
|End of Day Share Price||2020/07/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.